RXDX Ignyta, Inc.

7.05
+0.15  (2%)
Previous Close 6.90
Open 6.95
Price To book 4.98
Market Cap 294.94M
Shares 41,836,000
Volume 395,997
Short Ratio 1.70
Av. Daily Volume 538,908

SEC filingsSee all SEC filings

  1. 8-K - Current report 17848569
  2. 8-K - Current report 17826383
  3. 424B5 - Prospectus [Rule 424(b)(5)] 17814222
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17806232
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17801234

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data update 2H 2017.
RXDX-105
Solid tumors - cancer
Ongoing.
Taladegib
Ovarian cancer
Phase 2 trial initiated September 2015. Noted April 27, 2017 that enrollment will be completed 3Q 2017 with data due 1H 2018.
STARTRK-2 entrectinib
Solid tumors - cancer

Latest News

  1. Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
  2. Ignyta Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  3. Ignyta Announces Pricing of Public Offering of Common Stock
  4. Here's Why Ignyta Dropped as Much as 19.9% Today
  5. Ignyta Announces Proposed Public Offering of Common Stock
  6. Ignyta reports 1Q loss
  7. Ignyta Announces First Quarter 2017 Company Highlights and Financial Results
  8. Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions
  9. Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017
  10. Ignyta Announces New Data Highlighting Broad Potential of Both RXDX-106 and Entrectinib at the 2017 AACR Annual Meeting
  11. Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology
  12. Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
  13. Ignyta Announces Exploration of Strategic Options for Taladegib, Enabled by Amendment of Taladegib License Agreement with Lilly
  14. Ignyta Announces Full Year 2016 Company Highlights and Financial Results
  15. Angsana's RNA-based fusions cancer panel selected for Ignyta's STARTRK2 clinical trial in Asia-Pacific
  16. Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery
  17. Ignyta to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
  18. Ignyta to Present at 35th Annual J.P. Morgan Healthcare Conference
  19. Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018
  20. Ignyta, Inc. :RXDX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016

SEC Filings

  1. 8-K - Current report 17848569
  2. 8-K - Current report 17826383
  3. 424B5 - Prospectus [Rule 424(b)(5)] 17814222
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17806232
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17801234
  6. 8-K - Current report 17801089
  7. DEF 14A - Other definitive proxy statements 17795317
  8. 8-K - Current report 17790060
  9. 8-K - Current report 17737132
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17731123